ATE187724T1 - Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung - Google Patents

Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung

Info

Publication number
ATE187724T1
ATE187724T1 AT93114934T AT93114934T ATE187724T1 AT E187724 T1 ATE187724 T1 AT E187724T1 AT 93114934 T AT93114934 T AT 93114934T AT 93114934 T AT93114934 T AT 93114934T AT E187724 T1 ATE187724 T1 AT E187724T1
Authority
AT
Austria
Prior art keywords
azachinoxalines
production
formula
image
substituents
Prior art date
Application number
AT93114934T
Other languages
German (de)
English (en)
Inventor
Uta-Maria Billhardt-Troughton
Manfred Dr Roesner
Rudolf Dr Bender
Christoph Dr Meichsner
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of ATE187724T1 publication Critical patent/ATE187724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT93114934T 1992-09-26 1993-09-16 Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung ATE187724T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232392 1992-09-26

Publications (1)

Publication Number Publication Date
ATE187724T1 true ATE187724T1 (de) 2000-01-15

Family

ID=6468974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93114934T ATE187724T1 (de) 1992-09-26 1993-09-16 Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung

Country Status (20)

Country Link
US (1) US5424311A (en, 2012)
EP (1) EP0590428B1 (en, 2012)
JP (1) JPH06211855A (en, 2012)
KR (1) KR940007035A (en, 2012)
AT (1) ATE187724T1 (en, 2012)
AU (1) AU664643B2 (en, 2012)
CA (1) CA2106882C (en, 2012)
CZ (1) CZ9302005A3 (en, 2012)
DE (1) DE59309902D1 (en, 2012)
DK (1) DK0590428T3 (en, 2012)
ES (1) ES2141744T3 (en, 2012)
GR (1) GR3032520T3 (en, 2012)
HU (1) HUT65302A (en, 2012)
IL (1) IL107081A (en, 2012)
MX (1) MX9305894A (en, 2012)
NZ (1) NZ248762A (en, 2012)
PH (1) PH30348A (en, 2012)
PT (1) PT590428E (en, 2012)
TW (1) TW274550B (en, 2012)
ZA (1) ZA937081B (en, 2012)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510695A (ja) * 1994-01-03 1997-10-28 エイシア・ファーマシュウティカルズ，インコーポレイテッド ８−アザ、６−アザ、および６，８−ジアザ−１，４−ジヒドロキノキサリン−２，３−ジオン類およびそのグリシン／ｎｍｄａリセプターに対するアンタゴニストとしての使用
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
CA2313789A1 (en) 1998-07-16 2000-01-27 Aaron Tabor Soy formulations and their use for promoting health
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ME00541B (me) * 2003-05-23 2011-10-10 Zentaris Gmbh NOVI PIRIDOPIRAZINI I NJlUHOVA UPOTREBA KAO MODULATORA KlNAZA
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP4436892B2 (ja) * 2006-04-21 2010-03-24 ファイザー・プロダクツ・インク ピリジン［３，４−ｂ］ピラジノン
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0614471D0 (en) * 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
KR101504669B1 (ko) * 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
ES2383370T3 (es) * 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
US8372114B2 (en) * 2006-11-13 2013-02-12 Electroformed Stents, Inc. Over-the-wire exclusion device and system for delivery
US8329695B2 (en) * 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
TWI557117B (zh) 2008-12-09 2016-11-11 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
EP2389379A1 (en) 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
ES2661850T3 (es) * 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
KR101903925B1 (ko) 2009-10-26 2018-10-02 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
PH12012501581A1 (en) * 2010-02-03 2012-10-22 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EA034512B1 (ru) 2011-10-19 2020-02-14 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение злокачественной опухоли ингибиторами tor-киназы
JP2015501793A (ja) 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ，エルエルシー ジヒドロプテリジノン類
ES2694413T3 (es) 2011-12-02 2018-12-20 Signal Pharmaceuticals, Llc Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
AU2013202305B2 (en) 2012-02-24 2015-03-12 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP2016505041A (ja) 2013-01-16 2016-02-18 シグナル ファーマシューティカルズ，エルエルシー 置換型ピロロピリミジン化合物、その組成物、およびこれらを用いた治療方法
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
MX380689B (es) 2013-04-17 2025-03-12 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
EP2986609B1 (en) 2013-04-17 2019-06-19 Signal Pharmaceuticals, LLC Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
UA115805C2 (uk) 2013-04-17 2017-12-26 Сігнал Фармасьютікалз, Елелсі Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
MX2017003288A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Metodos para preparar modulares de receptor tipo toll.
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
AU2018289539B2 (en) 2017-06-22 2024-07-04 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
KR102272284B1 (ko) * 2020-01-13 2021-07-02 금오공과대학교 산학협력단 정밀 압력제어가 가능한 다단 스프링 압력제어밸브
WO2025085564A1 (en) * 2023-10-16 2025-04-24 Kronos Bio, Inc. Lysine acetyltransferase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
PH15791A (en) * 1978-10-20 1983-03-25 Lilly Co Eli Pharmaceutical composition containing 3,4-dihydro-3-oxoquinoxalines
IE58312B1 (en) * 1984-05-18 1993-09-08 Union Pharma Scient Appl Heterocyclic derivatives, processes for their preparation and drugs in which they are present, which are useful especially as aldose reductase inhibitors
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DK160876C (da) * 1987-12-08 1991-10-14 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar
ATE205837T1 (de) * 1991-04-15 2001-10-15 Aventis Pharma Gmbh Chinoxaline, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
PT590428E (pt) 2000-04-28
DE59309902D1 (de) 2000-01-20
AU664643B2 (en) 1995-11-23
IL107081A (en) 1999-07-14
PH30348A (en) 1997-04-02
EP0590428B1 (de) 1999-12-15
IL107081A0 (en) 1993-12-28
US5424311A (en) 1995-06-13
HU9302696D0 (en) 1993-12-28
ES2141744T3 (es) 2000-04-01
AU4755393A (en) 1994-03-31
TW274550B (en, 2012) 1996-04-21
GR3032520T3 (en) 2000-05-31
CA2106882C (en) 2007-04-17
CA2106882A1 (en) 1994-03-27
ZA937081B (en) 1994-04-18
EP0590428A1 (de) 1994-04-06
HUT65302A (en) 1994-05-02
MX9305894A (es) 1994-03-31
DK0590428T3 (da) 2000-05-22
NZ248762A (en) 1996-01-26
JPH06211855A (ja) 1994-08-02
CZ9302005A3 (en) 1994-04-13
KR940007035A (ko) 1994-04-26

Similar Documents

Publication Publication Date Title
ATE187724T1 (de) Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung
ATE205837T1 (de) Chinoxaline, verfahren zu ihrer herstellung und ihre verwendung
ATE230732T1 (de) Imidazol-derivate mit biphenylsulfonylharnstoff- oder biphenylsulfonylurethan-seitenkette, verfahren zu ihrer herstellung und ihre verwendung
ATE20738T1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses.
DE3482180D1 (de) Cyclohexenol-derivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses.
DE3576955D1 (de) Beta-carbolin-3-oxadiazolylderivate, verfahren zu ihrer herstellung und ihre verwendung.
PT77924A (de) Disubstituierte prolinderivate verfahren zu ihrer herstellung und ihre verwendung
ATE181056T1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
ATE104296T1 (de) Substituierte 1,2,4-triazindione, verfahren zu ihrer herstellung und ihre verwendung.
DE3578178D1 (de) Beta-carbolin-3-carbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung.
ATE184003T1 (de) 4-iminochinoline, verfahren zu ihrer herstellung und ihre verwendung
DE3673468D1 (de) N-alkyl-2,6-dimethylmorpholinio-carbonsaeureamid-salze, verfahren zu ihrer herstellung und ihre verwendung als fungizide.
DE59905700D1 (de) N-phenylacetoacetamide und Verfahren zu ihrer Herstellung
ATE8046T1 (de) Dibenzofuranderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von pilzen.
ATE85327T1 (de) Substituierte pyridylethanolamine, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer bei tieren.
ATE8390T1 (de) Vinylazole, verfahren zu ihrer herstellung und ihre verwendung bei der bekaempfung von pilzen.
ATE113598T1 (de) Substituierte vinylcephalosporine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE9337T1 (de) N-substituierte 2-methylnaphthylamide, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von pilzen.
DE3578866D1 (de) 2,3-diamino-2,3-didesoxyhexose-derivate, verfahren zu ihrer herstellung und ihre verwendung.
DE59001431D1 (de) 1-methoxypyrimidinyl-1h-1,2,4-triazol-3-sulfonsaeurenitroanilide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung.
ATE111903T1 (de) Substituierte 1.2.3.4-oxatriazolium-5-olate, verfahren zu ihrer herstellung und ihre verwendung.
ATE66463T1 (de) 1,4-cyclohexandiamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide.
DE3868948D1 (de) 4,4-dimethyltetrahydropyr-2-on-derivate, verfahren zu ihrer herstellung und ihre verwendung zur synthese von pyretrinverbindungen.
ATE151736T1 (de) 2-arylpropensäuren und ihre verwendung bei der herstellung von s-ketoprofen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee